Core Viewpoint - Qizheng Tibetan Medicine has announced that its subsidiary, Tibet Tibetan Medicine Group Co., Ltd., has received approval for its Ten Flavor Gentian Flower Capsule as the first secondary protected traditional Chinese medicine, with a protection period of seven years from the announcement date [1] Group 1: Product Approval and Market Impact - The Ten Flavor Gentian Flower Capsule is indicated for clearing heat, resolving phlegm, stopping cough, and relieving asthma, primarily used in the treatment of respiratory diseases [1] - This approval is expected to enhance the company's market competitiveness in the respiratory field [1] - The approval will also promote the upgrading of Tibetan medicine quality standards and optimization of product quality [1] Group 2: Market and Regulatory Considerations - The production and sales of the drug are subject to various factors, including market environment changes and industry policies, which introduce a degree of uncertainty [1]

证券代码：002287 证券简称：奇正藏药 公告编号：2026-002 审批结论：根据《中药品种保护条例》规定，国家药品监督管理局批准西藏 藏药生产的十味龙胆花胶囊为首家中药二级保护品种，保护期限自公告日起七 年。 二、产品简介 西藏奇正藏药股份有限公司 关于十味龙胆花胶囊获批国家中药二级保护品种的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2026年1月20日，国家药品监督管理局网站发布了《中药保护品种公告（第 34号）》(2026年第11号），国家药品监督管理局批准西藏奇正藏药股份有限公司 （以下简称"公司"）控股子公司西藏藏药集团股份有限公司（以下简称"西藏 藏药"）的十味龙胆花胶囊为首家中药二级保护品种。现将相关情况公告如下： 一、药品基本信息 药品名称：十味龙胆花胶囊 功能主治：清热化痰，止咳平喘。用于痰热壅肺所致的咳嗽、喘鸣、痰黄， 或兼发热、流涕、咽痛、口渴、尿黄、便干等症；急性气管炎、慢性支气管炎急 性发作见以上证候者。 保护品种号：ZYB2072026004 十味龙胆花胶囊，清热化痰，止咳平喘，是主治"咳、痰、喘、炎、热"的 经典藏 ...

Core Viewpoint - As of January 9, 2026, the total number of shareholders for Qizheng Pharmaceutical is reported to be 30,783 households [2] Company Summary - Qizheng Pharmaceutical has engaged with investors through an interactive platform, providing transparency regarding its shareholder base [2] - The company is actively communicating with its investors, indicating a focus on shareholder engagement and investor relations [2]

Group 1 - The core point of the article is that Qizheng Tibetan Medicine announced the approval of multiple proposals, including a proposal to apply for comprehensive credit from banks during its first extraordinary shareholders' meeting of 2026 [2] Group 2 - The company is actively seeking to enhance its financial capabilities through bank credit, indicating a strategic move to support its operations and growth [2] - The announcement reflects the company's ongoing efforts to engage with its shareholders and maintain transparency regarding its financial strategies [2] - The approval of the proposals suggests a positive outlook from shareholders regarding the company's future financial initiatives [2]

股东会法律意见书 北京海润天睿律师事务所 关于西藏奇正藏药股份有限公司 2026 年第一次临时股东会的法律意见书 中国·北京 朝阳区建外大街甲 14 号广播大厦 5/9/10/13/17 层 二〇二六年一月 股东会法律意见书 北京海润天睿律师事务所 关于西藏奇正藏药股份有限公司 2026 年第一次临时股东会的法律意见书 致：西藏奇正藏药股份有限公司 一、本次股东会的召集、召开程序 经本所律师审查，公司董事会关于召开本次股东会的通知已于 2025 年 12 月 23 日在巨潮资讯网（http://www.cninfo.com.cn）等指定信息披露媒体上披露。 通知中载明了召开会议的基本情况、会议审议事项、会议登记等事项、参加网络 投票的具体操作流程等事项。 北京海润天睿律师事务所（以下简称本所）接受西藏奇正藏药股份有限公司 （以下简称公司）的委托，指派本所律师出席公司 2026 年第一次临时股东会并 对本次股东会进行律师见证。 对本法律意见书的出具，本所律师特作如下声明： 1、本所律师仅就本次会议的召集、召开程序、出席本次股东会的人员资格、 召集人资格、本次股东会的表决方式、表决程序及表决结果发表意见，不对本次 ...

证券代码：002287 证券简称：奇正藏药 公告编号：2026-001 西藏奇正藏药股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 1、本次股东会无否决或修改议案的情况； 2、本次股东会不涉及变更前次股东会决议的情况。 一、会议召开情况和出席情况 1、会议召集人：西藏奇正藏药股份有限公司（以下简称"公司"）第六届董 事会； 2、表决方式：现场投票与网络投票相结合方式； 3、会议时间 3.1 现场会议时间：2026年1月7日（星期三）下午14:30； 3.2 网络投票时间：2026年1月7日，其中，通过深圳证券交易所交易系统进 行网络投票的时间为2026年1月7日9:15－9:25、9:30－11:30、13:00－15:00； 通过深圳证券交易所互联网投票系统投票的时间为2026年1月7日9:15－15:00。 4、现场会议召开地点：北京市朝阳区望京北路9号叶青大厦D座7层公司会议 室； 7.3 公司董事和董事会秘书出席了会议，总裁、高级管理人员和见证律师列 席了本次会议。 二、议案审议表决情况 本 ...

Core Viewpoint - As of December 19, 2025, the total number of shareholders for Qizheng Pharmaceutical (002287) is reported to be 30,738 households [1] Company Information - Qizheng Pharmaceutical has engaged with investors through an interactive platform, providing updates on shareholder numbers [1] - The company is actively communicating with its investors, indicating a focus on transparency and shareholder engagement [1]

Group 1 - The company, Qizheng Tibetan Medicine, announced that it will hold its first extraordinary shareholders' meeting for 2026 on January 7, 2026 [1]

Group 1 - The company Qizheng Tibetan Medicine announced a total guarantee amount of 900 million yuan, which accounts for 22.14% of the latest audited net assets [1] - As of the announcement date, the total external guarantee balance of the company and its subsidiaries is approximately 627 million yuan, representing 15.42% of the latest audited net assets [1] - The company has no overdue external guarantees, no guarantees involved in litigation, and no losses due to guarantees resulting in adverse judgments [1] Group 2 - The company's revenue composition for the first half of 2025 shows that the pharmaceutical industry accounts for 99.39%, while other sectors account for 0.61% [1] - The market capitalization of Qizheng Tibetan Medicine is currently 13.9 billion yuan [2] - The new energy heavy truck industry has seen a significant increase in sales, with a year-on-year growth of 178% in November, indicating strong demand [2]

Group 1 - The core viewpoint of the article highlights that Qizheng Tibetan Medicine (SZ 002287) held its 16th meeting of the 6th board of directors on December 22, 2025, via electronic communication, discussing the proposal for the 2026 first extraordinary shareholders' meeting [1] - For the first half of 2025, Qizheng Tibetan Medicine's revenue composition was 99.39% from the pharmaceutical industry and 0.61% from other sources [1] - As of the report date, Qizheng Tibetan Medicine's market capitalization was 13.9 billion yuan [1] Group 2 - The article also notes a significant increase in the sales of new energy heavy trucks, with November sales experiencing a year-on-year growth of 178% [1] - The demand for these trucks is so high that customers are directly urging manufacturers for orders, indicating a supply shortage [1] - This surge in demand is described as a rare occurrence in the past decade [1]